Sign Up For Free » Here's a closer look at three discounted S&P 500 dividend stocks you can feel good about buying and ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday.

Eli Lilly has unveiled a $27 billion (€25.7 billion) investment in US manufacturing facilities as the pharmaceutical industry ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Shakur Stevenson's chances of beating Gervonta Davis have been brutally played down. Stevenson was able to stop late replacement and part-time electrician Josh Padley in a hard-fought win in ...